- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Rx marketing 'e-events' increasing
The Internet has become a new meeting place for drug companies and doctors, according to the Physician Meeting and Event Audit from Newtown, PA-based Scott-Levin. From February through April 2001, Scott-Levin surveyed its PMEA panel every month to determine the extent of "e-event" activity. More than 3,100 physicians participated in the study; 39% indicated that they had been invited to at least one pharmaceutical company-sponsored event conducted via the Internet.
The Internet has become a new meeting place for drug companies and doctors, according to the Physician Meeting and Event Audit from Newtown, PA-based Scott-Levin. From February through April 2001, Scott-Levin surveyed its PMEA panel every month to determine the extent of "e-event" activity. More than 3,100 physicians participated in the study; 39% indicated that they had been invited to at least one pharmaceutical company-sponsored event conducted via the Internet.
Specialists with the highest percentages of e-event invitations were allergists/immunologists (58% invited), psychiatrists (53%) and gastroenterologists (51%).
In addition, 30% of doctors said their attitude toward e-events was positive, and 64% said they planned to participate in future events.
Research Triangle Park, NC-based GlaxoSmithKline led in e-events offered during the spring, accounting for more than 14% of activity, followed by Whitehouse Station, NJ-based Merck & Co. Inc., with almost 13% of e-events. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
